Supplementary Table 4.docx (27.05 kB)

Supplementary Table 4: Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase 3 safety study

dataset

posted on 2021-11-18, 09:13 authored by Shin-ichi Konno, Takuya Nikaido, John D Markman, Makoto Ohta, Toshiya Machida, Naoki Isogawa, Hiroki Yoshimatsu, Lars Viktrup, Mark T Brown, Christine R West, Kenneth M Verburg

Supplementary Table 4. Tanezumab for Chronic Low Back Pain: A Long-term, Randomized, Celecoxib-Controlled, Japanese, Phase 3, Safety Study

Summary of TEAEs of possible decreased sympathetic function through week 80 (treatment + follow-up periods)

Funding

Eli Lilly & Company, Pfizer

History

Usage metrics

Read the peer-reviewed publication

Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase 3 safety study

Pain Management

Keywords

tanezumab celecoxib chronic low back pain Japan safety efficacy randomized clinical trial Clinical Sciences not elsewhere classified Neurosciences not elsewhere classified

Licence

CC BY-NC-ND 4.0